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Abstract (200 words) 
 
Brain imaging is essential for the diagnosis and characterization of cerebral small vessel disease (SVD). 
Several magnetic resonance imaging (MRI) markers have therefore emerged, providing new information 
on the diagnosis, progression and mechanisms of SVD. Yet, the reproducibility of these SVD markers 
has received little attention despite being widely used in cross-sectional and longitudinal studies. This 
review focuses on the main SVD-related markers on MRI including: white matter hyperintensities, 
lacunes, dilated perivascular spaces, microbleeds and brain volume. The aim is to summarise, for each 
marker, what is currently known about: 1) its reproducibility in studies with a scan-rescan procedure 
either in single or multi centre settings; 2) the acquisition-related sources of variability; and, 3) the 
techniques used to minimise this variability. Based on the results, we discuss technical and other 
challenges that need to be overcome in order for these markers to be reliably used as outcome 
measures in future clinical trials. We also highlight the key points that need to be considered when 
designing multicentre MRI studies of SVD. 
Keywords: MRI, cerebral small vessel disease, marker, brain volume, atrophy, white matter 
hyperintensities, microbleeds, lacunes, perivascular spaces, reproducibility, repeatability, variability 
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1. Introduction 
 
Cerebral small vessel disease (SVD) is a major source of cognitive impairment and is the 
second most common cause of dementia in older aged people.1 SVD is typically sporadic and related to 
aging and vascular risk factors, but can also be caused by genetic conditions2. The most frequent 
sporadic forms of SVD are arteriolosclerosis and cerebral amyloid angiopathy (CAA). A significant 
proportion of patients with SVD have associated neurodegenerative diseases such as Alzheimer’s 
Disease (AD), which can lead to a mixed dementia.3 In therapeutic trials for dementias, surrogate 
imaging markers of both pathophysiological processes should ideally be used to account for the 
potential mixed origin. 
Pathological features of SVD are heterogeneous and out of reach of current in vivo imaging 
techniques. Nonetheless, parenchymal lesions presumed to be caused by small vessel changes have 
been adopted as markers of SVD, giving neuroimaging a central role for diagnosis and 
characterization4. The spectrum of brain magnetic resonance imaging (MRI) manifestations of SVD is 
wide, ranging from minor white matter hyperintensities (WMH) often seen in population-based studies to 
numerous subcortical lesions. Indeed, MRI using various sequences allows an evaluation of several 
imaging markers related to SVD, including recent small subcortical infarcts, WMH, lacunes, enlarged 
perivascular spaces (PVS), cerebral microbleeds (CMB), and brain atrophy, as summarized by an 
international working group defining neuroimaging standards (STRIVE) for research into SVD5. 
The uncertain or lower reproducibility of these MRI markers, especially across centres, is a 
major concern in cross-sectional and longitudinal observational studies as well as in clinical trials. 
Indeed, a key challenge is to minimize the variability caused by technological and subject-related 
factors. Such variability may confound the detection of disease- or treatment-related MRI changes, 
thereby limiting the power to detect and follow the progression of imaging markers of SVD. From the 
patient being imaged to the final imaging marker of interest, which is quantified by an expert rater or an 
automatic image-processing algorithm, there are several sources of variability. These can include 
subject-related physiological changes or instrument-related factors such as field strength, head coil, 
gradients and sequence parameters (see Fig. 1). Each can affect the reproducibility of the marker. 
Additional variation may be introduced at the image post-processing stage, depending on which 
software is used for inhomogeneities correction or tissue segmentation, for example. The definition of 
lesions and the interpretation of images by several experts may be other sources of variability. The 
measurement of each MRI marker therefore depends on several factors, the effects of which need to be 
minimized, corrected or taken into account in a posteriori analyses for studies to be comparable. 
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The aims of this review are to summarise current knowledge regarding the reproducibility and 
variability of quantitative imaging markers of SVD including WMH, lacunes, PVS, CMB and brain 
volume in both single centre and multicentre contexts. To highlight technical solutions for common 
problems and to identify the remaining challenges that need to be overcome for such markers to be 
considered valid and reliable. Other SVD-related MRI markers, due to their acute manifestation (recent 
small subcortical infarct) or their so far non-quantitative assessment (cortical superficial siderosis, 
cortical microinfarcts) have not been examined in reproducibility studies to our knowledge and hence 
were not included in the literature search. Post-processing tools or expert ratings that also contribute to 
the global variability and accuracy of the final marker measurement are beyond the scope of this review. 
For each MRI marker of SVD we review: 1) its reproducibility in studies with a scan-rescan design in 
single or across multiple centres; 2) the acquisition-related sources of variability; and, 3) the techniques 
that can be used to minimise methodological limitations. We also discuss those factors that need to be 
considered to deal with image variability inherent in MRI markers in multicentre design studies such as 
clinical trials or longitudinal studies. 
2. Methods	  
Search strategy and selection criteria 
This review was designed to focus on the reproducibility and variability of well-defined MRI 
markers of SVD: WMH, lacunes, PVS, CMB and brain volume. 
For each biomarker, taking into account the vocabulary heterogeneity of each marker (see 
supplementary material), a PubMed search has been conducted up to August 2015 14th with the 
associated terms “MRI” AND (“variability” OR “reproducibility” OR “reliability” OR “consistency”). Papers 
published before 2002 were not considered to focus on recent MR technology. Reviews, conference 
abstracts and articles not written in english were excluded from analysis. Articles from our personal 
databases were also incorporated to the search. To be included in the reproducibility summary (Table 
1), studies had to include subjects who underwent a scan-rescan procedure either at the same centre 
or/and at different centres. Filtering was firstly based on review of the title and abstract for relevance.  
Studies were not mandatorily related to SVD (e.g., multiple sclerosis or AD) to include the largest 
number of studies about variability and reliability for the MRI markers of interest. 
Term and metrics definitions 
As the development and implementation of quantitative imaging biomarkers has been 
hampered in part by inconsistent use of terminology, an interdisciplinary group of radiologists, 
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statisticians, physicists, and other researchers worked to develop a comprehensive terminology to serve 
as a foundation for quantitative imaging biomarker claims6. Definitions agreed are reproduced in 
supplementary material.  
In order to simplify the manuscript reading, we will only use the terms “within-centre 
reproducibility” (strictly speaking, the repeatability) to report results from scan-rescan procedures in a 
single centre; and “between-centre reproducibility” to report results from multicentre studies.  
Several metrics are used to measure variability or reproducibility across different studies. A brief 
description of each is included in supplementary material. 
3. Results	  
3.1 Variation in the number of studies and in the evaluation of the 
reproducibility  
Number of studies 
There was large variation in the number of studies conducted for assessing the reproducibility 
and variability of each SVD MRI marker. Brain volume and brain atrophy measures have received the 
most attention (19 studies with within or/and between centre repeated scans of the same subjects)7-22. 
This is probably related to the significant imaging research efforts in AD community during the last 
decade in which cerebral atrophy was of primary concern. Particularly, the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) permitted the most important studies on this aspect, including repeated 
examinations of the same subject on the same or on different scanners 14, 17. Only five studies were 
found that evaluated the within-centre or between-centre variability of WMH measures13, 23-26(Table 1). 
Few studies examined the potential sources of variability of WMH volumes, despite a large number of 
image processing techniques attempting to quantify them accurately. Finally, there were only four 
studies on CMB25, 27-29 and no study on the variability of PVS and lacunes. This probably reflects the 
absence of consensus until recently about radiological terminology and definitions as well as difficulties 
to automatically quantify these markers30. Indeed, computational segmentation of lacunes and 
perivascular spaces has not yet been validated in a specific study. Overall, the reproducibility of 
measure of longitudinal change, i.e. the evolution of a given marker as a function of time, has only been 
evaluated for brain volume change (brain atrophy) in 4 studies9, 17, 19, 22 and not for other markers.  
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Evaluation of reproducibility 
Several studies with a scan-rescan procedure selected in this review included different 
measures of variability in volumetric measurements that were not consistent across studies: intra-class 
coefficients, coefficients of variation, standard deviations, mean absolute values of differences. Hence, 
most of these studies were not directly comparable (Table 1). This prevented a quantified comparison 
between the multiple factors that may influence the measurements. It would be valuable for the 
community to harmonize measures of reproducibility and make sure that all important aspects of 
reproducibility are included. 
3.2 Reproducibility and variability of MRI markers 
  
3.2.1 White-matter hyperintensities (WMH) 
Definition and interest in SVD 
From a radiological perspective, WMH of presumed vascular origin have a higher signal 
intensity compared to the normal-appearing white matter on proton-density (PD)-weighted, T2-weighted 
and FLAIR (Fluid-attenuated inversion recovery) sequences and may appear iso- or hypointense on T1-
weighted images5. It is widely accepted that WMH are important for clinical outcome, in terms of 
cognitive and functional impairment5, 31. Many qualitative and quantitative techniques have been used to 
measure WMH. Qualitative approaches are based on visual rating scales completed by well-trained 
readers32-­‐34. Quantitative techniques involve image-processing algorithms to obtain volumetric 
measures or spatial distribution of WMH lesions35-39. In this review, we only focused on quantitative 
techniques, as they offer a continuous measure that is a more reliable and sensitive alternative to visual 
rating scales40.  
Within-centre reproducibility 
Several studies found good to excellent reproducibility of WMH segmentation and volumetry for 
different computational image analysis methods using a scan-rescan procedure in a single site13, 23, 26 
(Table 1). For example, in the study recruiting the largest number of subjects, De Boer et al.13 assessed 
the within-centre reproducibility of WMH segmentation by comparing computational segmentation in 30 
subjects scanned twice within a short interval at 1.5T. They found with their best segmentation pipeline 
a mean (sd) WMH volume difference expressed in % of intracranial volume of 0.01% (± 0.05%) and a 
coefficient of variation less than 6%. 
Between-centre reproducibility (effect of various vendors, coils)  
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No report was found about between-centre reproducibility of WMH measures in large cohorts 
evaluated in several centres and using the same magnetic field. 
Magnetic field effect 
It is not clear how the magnetic field strength impacts the measurement of WMH volume 
beyond the expected improved resolution at higher field. Indeed there are relatively few direct 
comparisons of different scanner field strengths in any situation41.	  In 10 patients with SVD, Theysohn et 
al. showed that FLAIR images acquired at 7T highlighted WMH known from 1.5T with comparable 
extent 25. However, WMH were not adequately quantified in this study as neither number nor volume 
was assessed. On the contrary, in patients with multiple sclerosis, it has been reported that 3T scans 
showed a mean 10% higher WMH volume compared to 1.5T scans in total lesion volume based on PD-
weighted images24. 
Sequence effect 
WMH detection and automated quantification usually relies on the FLAIR sequence, which 
produces T2-weighted images with cerebrospinal fluid suppression. It has been recently shown that 3D 
FLAIR sequence parameters could be optimized to increase lesion detection and identification in 
multiple sclerosis compared with default 3D FLAIR or 2D FLAIR (Fig. 2)42. This approach might also be 
used in SVD. Indirectly, this study showed that MR parameters (echo time, inversion time) influences 
the tissue contrast between the normal white matter and white matter lesions on which the algorithms to 
segment WMH heavily depend. 
Some pipelines have used an interleaved PD/T2 acquisition for WMH segmentation, especially 
as this dual spin echo sequence is more sensitive to WMH in the deep basal ganglia and thalamus than 
FLAIR and also allows better detection of perivascular spaces60,43. Multisequence image analysis 
approaches to quantify WMH, eg which combine FLAIR with T2* or T1 or T2 or several sequences 
together, are increasingly used and emphasise the need to obtain several key standard sequences 
when studying SVD. 
Partial volume effects 
 Partial volume effect is the combination of signals from different tissue types in a single voxel 
whose image intensity is thus dependent on proportions of each tissue. Partial volume effects with 
clinically feasible resolutions complicate delineation of the lesion borders44. Particularly, smaller voxel 
sizes allow more accurate estimation and yield larger total lesion volumes, especially for patients with 
small lesions45. For example, in 10 patients with multiple sclerosis, lesion volumes were reported to be 
on average 9% greater with 3 mm compared to 5 mm slice thickness45.  
Other factors with some effects 
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The approach to post-processing for bias field (or B1 inhomogeneities) correction can have an 
important effect on WMH volume quantification according to the computational method used46. 
Reproducibility in longitudinal studies 
No study was found to assess the reproducibility of any longitudinal measurement of WMH. 
3.2.2 Lacunes and perivascular spaces 
Definition and interest in SVD 
 From a radiological perspective, lacunes of presumed vascular origin are round or ovoid, 
subcortical, fluid-filled cavities of between 3 mm and 15 mm in diameter, consistent with a previous 
acute small subcortical infarct or haemorrhage in the territory of one perforating arteriole5. Number, size, 
shape and location are measures of interest for lacunes. To date, very few automatic image processing 
methods exist to segment lacunes, and most studies rely on semi-automatic computational approaches 
or manual segmentations by trained observers37, 47-50. 
PVS are fluid-filled spaces that follow the typical course of a small vessel as it goes through 
grey or white matter and have a signal intensity similar to CSF on all sequences5, 51. Number, size, 
shape and location are measures of interest for PVS. Rating methods have been developed to describe 
these markers52, 53. To date, very few computational image processing methods exist to segment PVS 
though some are in development37, 54-56. The first image processing methods for both lacunes and PVS 
detection were not fully robust and efficient, requiring time-consuming user manual intervention but new 
methods are more automated and much faster. 
Within- or between-centre reproducibility 
 The literature is very sparse concerning the reproducibility of measurements describing lacunes 
or PVS51. In 20 subjects scanned twice on a 1.5T scanner, one study assessed a good reproducibility 
for lacunar volume with the used dedicated software but the extent or numbers of lacunes per subject 
were not specified 26.  
High-resolution images should be more sensitive for detecting lacunes and PVS because they 
are small. Therefore, their volume assessment may heavily depend on spatial resolution and 
geometrical inaccuracies induced by gradient nonlinearities.  
Reproducibility in longitudinal studies 
No study was found to assess the reproducibility of any longitudinal measurement for both 
lacunes and PVS. 
 
3.2.3 Cerebral microbleeds 
Definition and interest in SVD 
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 From a radiological perspective, cerebral microbleeds (CMB) associated with SVD are small 
hypointense lesions on paramagnetic sensitive MR sequences such as T2*-weighted gradient-echo 
(GE) sequence, and are most frequently located in the cortico-subcortical junction, deep grey or white 
matter in the cerebral hemispheres, brainstem and cerebellum5, 57. CMB are associated with SVD and 
lobar CMB are often seen in patients in memory clinics who have CAA 5, 58-60. Most studies suggest that 
they are associated with impaired cognitive function61, 62, although their direct clinical impact remains 
uncertain. Several rating scales have been designed to minimize observer variation63, 64 along with 
several post-processing algorithms for semi-automatic or automatic quantification65-69. We consider in 
this review all methods to study CMB as a few computational methods have been published and tested 
in reproducibility studies. Many MRI acquisition factors are expected to influence CMB detection as their 
size is a consequence of susceptibility effects that are highly dependent on MRI sequence parameters. 
In fact, hypointensities are typically larger than the physical size of the corresponding histopathological 
lesion (blooming effect)70.  
Within- or between-centre reproducibility 
 No study was found to assess CMB detection reproducibility through a scan-rescan procedure 
at the same centre or between centres with the same imaging protocol. However, several studies 
examined various factors involved in CMB detection such as magnetic field strength or sequence 
parameters. 
Magnetic field effect 
 Intravoxel dephasing due to susceptibility effects and associated signal loss in gradient-echo 
images increase with higher magnetic fields71. Several studies hence demonstrated an increased 
number of CMB at higher field strength25, 27, 29 with an increase in contrast to noise ratio27, 28 and CMB 
size25, 28 as illustrated in Fig. 3. For example, mean increases from 1.5T to 3T were 48% for contrast to 
noise ratio and 12% for CMB size on 119 CMB detected in 4 subjects70. In addition, more CMB are 
found at higher field strength; Theysohn et al. found 101 CMB at 7T (mean size: 3.2 mm) against 33 at 
1.5T (mean size: 1.4 mm) in 10 subjects25. 
Sequence effect 
 3D T2*-weighted gradient-echo images reveal significantly more CMB in more subjects 
compared to 2D T2*-weighted gradient-echo images, primarily because of higher spatial resolution72. In 
200 older aged participants, Vernooij et al. reported 71 subjects with at least one microbleed (median 
number 2.5) using the 3D sequence compared to 42 subjects (median number 1.0) with the 2D 
sequence. Likewise, the susceptibility weighted imaging (SWI) technique, which uses phase images to 
enhance susceptibility-related contrasts in the resulting image, is particularly sensitive to paramagnetic 
and ferromagnetic substances73. CMB are better delineated on SWI images compared to classic T2* 
	   11	  
images25, 28, 74, 75 (Fig. 3). Another study also confirmed that SWI detected more CMB than conventional 
T2* images (prevalence of 40% vs. 23%, total number was 284 vs. 219 in 141 patients)76. To note, the 
differentiation between CMB and vessels might be more difficult with SWI compared to T2* images 
although this is a matter of debate 75, 77. A last point is that susceptibility-weighted sequences are 
different according to vendors (e.g., ‘SWI’ for Siemens, ‘SWAN’ for General Electric, ‘VenoBOLD’ for 
Philips) and only the Siemens ‘SWI’ technique uses phase data. Therefore, the effect of vendor’s 
susceptibility-weighted technique on CMB detection needs further assessment. 
Sequence parameters effect 
 The echo time (TE) reflects the timescale on which dephasing occurs, with long echo times 
enabling more time for dephasing thereby enlarging the susceptibility effect. Thus, choice of TE directly 
impacts on the number and volume of microbleeds detected as well as the number of structures that 
may be mistaken for microbleeds (calcium or iron deposits, flow voids, etc.). Increasing TE improves the 
sensitivity to detect CMB but more artefacts are generated near air-tissues interfaces causing 
uncertainty about rating some lesions78, 79. Otherwise, thin MR imaging sections compared with thicker 
sections were associated with a small decrease in CMB diameter and a large increase of contrast (CMB 
signal relative to tissue signal) and thus an improved CMB detection (Fig. 3)28, due to a reduction of 
partial volume effects. 
Reproducibility in longitudinal studies 
No study was found to assess the reproducibility of any longitudinal measurement for CMB. 
3.2.4 Brain volume 
Definition and interest in SVD 
 Brain volumetry refers here to measures obtained through computational segmentation of high-
resolution anatomical images. Global brain volume, intracranial volume (classically used for 
normalization purpose) and brain parenchymal fraction (BPF, brain volume divided by intracranial 
volume) were considered in this review as these are important markers in SVD 80, 81, 82 , 83-85. For 
example, BPF has been associated with dementia rating scales and the modified Rankin score in 
CADASIL81, 86, a monogenic SVD2. In sporadic forms, brain volume was notably associated with the 
presence and progression of lacunes87. Gray matter, white matter or hippocampus volumes are 
sometimes specifically assessed and can be markers of interest in SVD studies, but were not included 
in this review as these structures depend more on post-processing stages. However, no study amongst 
any of the following has assessed the influence of SVD markers, particularly WMH, on the performance 
of any brain volume measurement methods. 
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Within-centre reproducibility 
 Overall, several studies reported a satisfactory within-centre reproducibility of brain volumetric 
measurements at 1.5T7, 10, 13-15, 17, 18 or 3T10, 14, 15, 18 with the main brain image processing suites 
(FreeSurfer88, 89, SPM90, FSL91, BrainVisa92). Table 1 presents per study the numbers of centres, 
subjects, rescans per subject and main results for reproducibility. For example, in a large cohort of 671 
subjects who underwent two successive 3D T1 weighted scans, the median of the relative absolute 
difference in brain volume was found to be less than 1% 17. However, the 90th percentile of the absolute 
value of the difference was reported at 5.11%, which is more than twice the value that would be 
expected for a Gaussian distribution. This highlights the importance of studying several statistical 
outcomes to infer the reproducibility beyond the median or mean value of the difference. Thus, little 
variability is added when measuring brain volume in a single centre without changing the conditions of 
acquisition, at least regarding commonly reported disease-related changes. It is worth noting that most 
studies with a scan-rescan design included small samples (all n< 50 except Cover et al.17) and recruited 
mainly healthy subjects (two studies with mild cognitive impairment (MCI) and AD patients14, 17	  and one 
study in multiple sclerosis16).   
Between-centre reproducibility (effect of various vendors, magnetic field strengths, coils)  
 Effects of combining several MRI vendors, static magnetic field strengths or coil designs on 
brain volumetry can be assessed in studies where subjects are scanned several times in different 
centres (Table 1). As expected, compared to the within-centre variability, the between-centre volume 
variability was much higher at 1.5T7, 8, 10, 11, 14, 15, 18, 65 and 3T10, 12, 14, 15, 18. In one of the largest 
multicentre studies with a scan-rescan procedure (a subset of ADNI database in which 172 subjects 
were rescanned once in 59 different MRI sites on 17 different scanner types), the effects of scanner 
hardware and imaging protocol on volume quantification were analyzed14. The most striking result was 
that the variance in volumetric measures was 10 times higher when subjects were imaged on different 
scanners compared to acquisitions on the same scanners. For example, for brain volume, the median 
(standard deviation) of the absolute within-subject variability was 0.3% (0.5%) vs. 4.8% (4.6%) for 
repeated scans on the same scanner vs. on different scanners. This was essentially explained by the 
scanner-dependent geometrical inaccuracies and by the differences in the gray to white matter tissue 
contrast from variation in the imaging sequences used and RF coils (while this contrast is obviously 
impacting gray matter and white matter volumes, it also influences the total brain volume 
computation14). Such geometric distortions originate from gradient field nonlinearity (in theory, a 
gradient system is supposed to produce an incremental magnetic field varying linearly with distance 
from isocenter) and the static field inhomogeneity, whilst the contrast between brain tissues is 
determined by a variety of sequence parameters. Both factors are dependent on the scanner hardware 
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(a combination of vendor, magnetic field and coil systems), which explained 30 to 50% of the variance 
of any volumetric measure in that study. In another study, 15 subjects underwent 4 scan sessions at 3 
sites with two different vendors10. Interestingly, combining data of different vendors and/or field strength 
did not significantly change the standard deviation of the volume differences across conditions relative 
to the test–retest reproducibility within a fixed MRI system. However, the mean volume difference did 
change within one standard deviation from zero for intracranial volume. 
Upgrades and repair 
 Only a few studies have examined the effects of MR systems upgrades and repairs on 
volumetric measurements. It appears that mixing volumes derived from data acquired across a major 
scanner upgrade (such as replacement of the magnet, gradient system and software) do not show 
significant changes, although volumes of some specific structures may show a slight scanner specific 
volume bias10. Similarly, consistent measures for brain structure volumes have been found before and 
after gradient coil replacement in a 3T system93. However, inadvertent differences in sequence 
parameters for example may be introduced during the upgrade (human error)94	  which can cause major 
variance between pre- and post-upgrade scans if not detected quickly. Scanner upgrade or replacement 
are almost impossible to avoid, and therefore centres should consider having longitudinal phantom and 
volunteer assessments for quality assurance and to calculate differences in brain volumetry across time 
that would allow conversion factors to be generated. 
Sequence effect 
 Use of 3D inversion prepared T1-weighted fast gradient-echo sequences for brain tissue 
segmentation and volumetry is universal nowadays. It is widely used for its contrast properties and is a 
standard for most MRI vendors. It is therefore easy to implement in multicentre studies. Other 
sequences such as multi-echo fast low angle shot sequences have similar contrast properties and 
showed comparable volume reproducibility from Bland-Altman plot analysis than the MPRAGE 
sequence for example10. However, comparison between volumes derived from both sequence types 
demonstrated significant biases in the mean volume difference, probably due to a differing T2* 
sensitivity10. 
Isotropic voxels are superior to non-isotropic voxels for accurate estimation of brain volume. In 
sequences with non-isotropic resolution, the choice of image orientation (sagittal, coronal or axial) 
naturally yields volumetric differences when comparing datasets acquired with different image 
orientations95. These differences may be due to partial volume averaging and susceptibility-induced 
geometric distortions. It is anticipated that these findings can be generalized to all MRI-derived metrics 
of brain volume. 
Contrast effect 
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 Variability of the tissue contrast, defined as the ratio between gray and white matter tissues 
image intensities on T1-weighted images, relates to the choice of MR sequence parameters such as 
echo time (TE), repetition time (TR), inversion time (TI) and flip angle (FA) along with the selection of 
field strength and coil. The contrast has been shown to have non-negligible influence on brain tissues 
segmentation and thus volumetry7, 14. For example, a 6% change in the average contrast led to a 2% 
change in the computed brain volume14,	  which is of a similar size as the annual change in brain volume 
seen in the early stages of AD so could easily be interpreted as a disease effect. Notably, datasets with 
a higher contrast have a lower variability, but here the effect of different burdens of WMH have not been 
tested. 
Subject-related factors 
 Physiological variability within the subject being imaged is a source of variability beyond the 
disease-related variability. It has even been suggested in a study of BPF variability in multiple sclerosis 
that the variability due to physiological and pathological causes is important and likely larger in 
magnitude than scan–rescan repositioning effects16. The authors found that the variance assigned to 
physiological fluctuations was nearly two times greater than the variance due to patient repositioning 
during scan-rescan. This implies that scan–rescan experiments might only provide a lower bound on the 
true error in repeated volumetric measurements from MRI exams. It is well known that the hydration 
status of an individual can affect the measurement of brain volume. Specifically, lack of fluid intake for 
16 hours has been found to result in a 0.55% decrease in cerebral volume and re-hydration an increase 
of 0.72% in brain volume96. In the ADNI dataset and a large cohort of multiple sclerosis patients there 
was a significant effect of time-of-day on the BPF, with a greater brain volume in the morning97. 
Similarly, brain volume varies with plasma sodium98. These results suggest potential acquisition time 
and hydration biases should be randomized or statistically controlled to account for the day-to-day brain 
volume fluctuations. 
Factors with no or little effect 
 Correction for so-called B1 inhomogeneities (variations of image intensity due to the 
radiofrequency field) was not found to substantially change the reproducibility of whole-brain volumetric 
measurements10,	   unlike its effect on WMH and focal infarcts99. Similarly, some studies found that 
greater acceleration factor in parallel imaging (this technique combines the signals of several coil 
elements in a phased array to reconstruct the image and finally improve the signal-to-noise ratio or 
reduce the scan time) had very little influence on test–retest accuracy12, 100. However, these studies 
tested the influence of acceleration factor in healthy controls. Results might be different if older aged 
subjects or patients move during the acquisition of the reference lines part of the parallel imaging 
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strategy. Finally, reproducibility of brain volumetric measures was also relatively unaffected by small 
differences in voxel geometry compared to the effects observed on measures of cortical thickness12. 
3.2.5 Brain atrophy 
Definition and interest in SVD 
 Brain atrophy is the difference of total brain volume between two time points computed by a 
dedicated image processing software from high-resolution anatomical images. Quantitative measures 
derived from high-resolution anatomical images are considered over atrophy scales (not covered in the 
present review) as the quantitative measures have better sensitivity to change over time101. Surprisingly, 
very few studies reported brain atrophy measurement in SVD cohorts102, 103. Several methods are 
available, such as SIENA, which estimates the percentage brain volume change of the same subject 
between two time points, by registering the two brain images together and resampling into the space 
halfway between the two104, 105 and the Boundary Shift Integral (BSI), that is an automated method that 
determines the total volume through which the boundaries of a given cerebral structure have moved106. 
One alternative method to assess brain atrophy is by performing tissue segmentation at both time 
points, but this approach suffers from a higher variability given the added variability of each 
measurement22. 
Within-centre reproducibility 
 Within-centre reproducibility of quantitative image-processing methods for atrophy assessment 
have been shown to be relatively high in several studies (Table 1)17, 9, 19. For example, a study using the 
ADNI dataset reported a 0.35% mean difference in 385 subjects acquired in more than 50 sites (105 
healthy controls, 195 subjects with MCI and 85 with AD) undergoing two SIENA measurements 12 
months apart17. Further, the 90th percentile of the difference was much larger than expected (1.33%) for 
a Gaussian distribution. These results should be compared to the annualized mean percentage brain 
volume change obtained in that study: -0.65%  ± 0.82% for healthy controls, -1.15% ± 1.21% for MCI, -
1.84% ± 1.33% for AD. 
Between-centre reproducibility (effect of various vendors, magnetic field strengths, coils)  
 Some studies have examined the between-centre reproducibility of atrophy measurements 
using SIENA17, 22, 107 or other image-processing techniques22. It has been shown that even with scanner 
of the exact same model, scanner drift (a shift in the magnet’s field) and inter-scanner variability may 
cancel out longitudinal brain volume change44. It is worth noting that compared to voxel-based 
morphometry approaches, SIENA, which corrects for differences in imaging geometry using the outer 
skull surface for both time points, reduced the effects of scanner drift and inter-scanner variability on 
longitudinal morphometric results107. Similarly, other registration-based algorithms such as BSI show 
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better reproducibility compared to segmentation-based techniques such as Freesurfer or SIENAX22. 
However, segmentation-based methods using atlases can be improved by using fine registration 
methods and age-relevant templates108.  
Evaluation of coil effects on volumetric measurements showed that a change from a 12- to a 
32-channel coil was responsible for a shift of 0.5% in the whole brain BSI100, which appears 
unacceptable as it corresponds to the annual atrophy rate observed in healthy subjects109. 
Finally, analysing the back-to-back scans of the ADNI dataset in 200 pairs of images (118 
subjects with 0-12 months pairs and 82 subjects with 6-24 months pairs), it has been reported than 3T 
was no more reproducible than 1.5T for the whole brain atrophy measure using SIENA110. 
Contrast effect 
 Atrophy measurement is strongly dependent on image contrast. Indeed, the error using BSI 
may exceed 100% if image contrast properties dramatically differ between the two scans in a 
measurement pair 111. For example, in 10 volunteers, a mean brain volume change of -0.43% has been 
measured versus a +1.85% change when the second scan was acquired with a flip angle equal to 12° 
instead of 25° (the flip angle directly impacts the image contrast).  
Noise effect 
Noise is an unwanted random signal from various origins including: the subject’s body, coils, 
electronics, nearby machinery, etc. The signal-to-noise ratio is often computed as the ratio of the 
average signal intensity over the standard deviation of the noise. Signal-to-noise ratio directly impacts 
BSI values as, for example, the position of the brain surface is seen to retract as noise in the second 
time point scan increases111. Thus, the average percent volume change progressively diverges from 
zero with increasing noise mimicking increased brain atrophy. 
Subject-related factors 
Motion will have an impact on atrophy measurement. For example, it has been reported that, as 
the amplitude of the motion in the second scan increases, the mean absolute brain and ventricular BSI 
brain volume changes as well as the associated standard deviation increase progressively111. However, 
the different levels of motion have been simulated in this latter study and the severity may have been 
overestimated. 
Subject’s head positioning in the magnet also influences brain atrophy measures. Indeed, 
nonlinear gradient distortions associated with shifts in the long magnet’s axis can significantly decrease 
the accuracy and precision of MRI-derived measures of brain atrophy assessed by SIENA112. These 
negative effects increase in magnitude with: (i) increases in the Z-distance (long magnet’s axis) 
between the brains to be compared at two time points; and, (ii) increases in the Z-distance from magnet 
isocenter to the center of the pair of brains to be compared112. Typical gradient distortion field for a T1-
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weighted acquisition is presented in Fig. 4. It shows the dramatic shifting experienced by voxels 
especially at the border of the brain and the need for accurate correction and repositioning of patients in 
longitudinal studies.  
3.3 Techniques to manage variability 
We have highlighted a large number of reasons why quantitative MRI markers of SVD may be 
variable beyond subject-related or disease-related factors. These sources of variability introduce 
significant barriers, and potential biases, to multicentre imaging studies of SVD. Fortunately, while 
adding variability to the measurements of markers is inherent to imaging studies, some techniques have 
been designed to reduce it.  
First, an optimised MRI protocol with high contrast-to-noise ratio, minimal artefacts and good 
reproducibility must be determined. Hereto, a methodological approach has been proposed to target a 
protocol with the highest possible reproducibility based on the assessment of quality measures21. The 
principle is to acquire several datasets including: within-subject within-centre datasets, between-
subjects between-centre datasets and between-subject within-centre datasets. By analysing the 
summary data quality and quantitative measures extracted with dedicated and validated software the 
desired optimal MRI protocol can be determined. 
 Second, to account for the problem of upgrades in longitudinal studies, Jovicich et al. advise 
planning a ‘system upgrade calibration study’ as part of the design, with subjects scanned shortly prior 
to and immediately after the upgrade so as to derive a correct estimation for potential systematic 
biases10. 
Third, several corrective techniques based on the MR system characteristics 113, 114 or using a 
dedicated phantom 112, 115, 116 have been developed to reduce the effects of gradient distortion on 
imaging reproducibility. The advantage of using a phantom travelling from one site to another is to apply 
a unified correction independently of the vendor’s own corrections. Correction for gradient nonlinearity 
and intensity non-uniformity reduces the variance of longitudinal changes in brain volumes and 
improves the accuracy for detecting subtle volumetric changes117. For example, in 208 subjects, the raw 
mean percentage of brain volume change was -0.59% against -0.46% when images were corrected for 
gradient nonlinearity and intensity non-uniformity117. However, if the expected group difference far 
exceeds brain volume change related to geometric distortions, the extra time and expense associated to 
the phantom-based correction needs to be carefully evaluated. 
Finally, the use of dedicated statistical methods is important in analysing multicentre MRI data. 
A simple a posteriori method to account for scanner hardware variability (combination of different 
	   18	  
devices, coil types and field strengths) is to include the scanner hardware as a covariate in regression 
models 14. Moreover, it has been shown that T1-weighted regional anatomical brain volume data can be 
reliably combined across 1.5T and 3T centres with the application of an appropriate correction 
procedure (regression-based correction function when data varied in a linear and systematic fashion)118. 
More sophisticated statistical methods such as linear mixed-effect models including protocol as well as 
individual MRI acquisition parameters have also emerged to more accurately model longitudinal 
changes (BPF and volume of WMH)	   119. Another statistical approach is based on the statement that 
classical inference testing is inappropriate because it is designed to detect differences and not to prove 
similarity. Equivalence testing has then been applied to determine if MRI-based measurements obtained 
under variable conditions can be pooled120. This could be generalized to all MRI-derived measurements. 
Otherwise, Moorhead et al. used scanner specific priors (probability mappings of tissue occupancy) in 
the segmentation pipeline to reduce tissue classification differences between scanners to improve 
statistical power. Interestingly, they found that the between scanner differences were not reduced to the 
level of within scanner variability, the ideal for scanner harmonisation121.  
Ultimately, central application of automatic quality assessment94,	  122	  and image processing on 
raw data, using consistent techniques, can reduce the variability introduced by a posteriori image 
processing across centres.   
3.4	  Suggestions	  for	  future	  research	  
A between-centre variability study in a large group of subjects, representing a range of types 
and burdens of SVD lesions, to assess the effects of vendor and field strength (protocols as close as 
possible) on reproducibility of SVD lesions and brain volumes is missing. So are experiments examining 
the effects of changing coil, correcting for gradient distortion or field heterogeneities, upgrading the 
system, or varying classical parameters such as TE, TI or TR, on the final WMH volume. Finally, WMH 
appears to be a reliable marker in single centre studies where all acquisition and processing parameters 
are kept constant, but additional studies are missing to infer the true reproducibility of WMH measures 
in a multicentre context. 
As for WMH, a multicentre study assessing the effect of scanner hardware (same magnetic field 
but different vendors and models) on CMB detection with a given optimized protocol would greatly add 
to the knowledge on the reliability of CMB detection. New data on methods of automated detection of 
CMB throughout different brain regions are needed. Also, the analysis of the potential effects of coil, 
and voxel size would be particularly useful. Finally, CMB can be used as a reliable marker in single 
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centre studies but additional efforts are needed to determine the sources of variability in multicentre 
data. 
For lacunes and PVS, more automated and validated image processing algorithms are 
required, followed by assessment of reproducibility through both within and between centres 
acquisitions. In view of the likely interactions between acquisition protocols and performance of analysis 
methods, the assessment of all SVD features should be included in any study that assesses reliability of 
WMH and/or CMB and/or atrophy quantification.  
4. Ten key points for assessing quantitative SVD markers in multicentre 
studies 
 
Based on our review of the current literature regarding reproducibility and acquisition-related 
sources of variability of MRI markers in SVD and on personal experiences, we propose the following 
key points should be considered when designing or analysing a multicentre MRI study in SVD. 
Obviously, prior to acquisitions, the scientific question should guide which marker is the focus, although 
opportunities to assess all SVD markers should be obtained where possible. Optimising acquisition for 
contrast, signal-to-noise ratio and spatial resolution is particularly important when imaging elderly or 
cognitively impaired patient populations who will not tolerate prolonged acquisition times. Importantly, 
although it is essential to have accurate and reproducible measurements, the nature of the questions 
will be guiding the level of precision that is needed. Requirements might be different between 
interventional clinical trials with relatively short term duration and long-term population-based 
observational studies. For example, in some situations, the added noise due to multicentre variability 
will not alter a strong statistical association between one SVD-related MRI marker and one clinical 
outcome. Conversely, studying the quantitative evolution of one SVD-related marker during a short 
follow-up will require a very fine quantification that necessitates a variability caused by technological 
factors as small as possible. Hence we organized our recommendations as being a) advisable whatever 
the question guiding the study as they tackle effects being important and/or involve easy-to-follow 
techniques to manage variability, b) advisable in some conditions, i.e. when the expected effect of 
interest is small relatively to the unwanted noise caused by the multicentre setting.  
 
a) strongly advisable and easy-to-follow recommendations 
 
1. Automated quality checks for MRI sequence parameters are advisable (for each scan, 
comparison of the acquisition parameters with the intended protocol for each scanner). Also, 
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images should be monitored for motion and other artefacts such as magnetic susceptibility 
artefacts, aliasing artefacts or Gibbs artefacts. A minimum standard for quality control will have 
to be defined to exclude problematic data (for example, based on the severity of artefacts or 
from automatic measures of signal to noise ratio, background noise, etc.). Indeed, even if the 
computational method seems to run properly, artefacts can dramatically alter the data. 
2. MRI gradient nonlinearities have to be corrected at least with corrections proposed in options by 
the manufacturer as they can affect dramatically measures of brain atrophy. 
3. Subject’s positioning in the scanner is another key aspect and strict instructions for MR 
technicians may be particularly useful to reproduce confidently the position of the head, from 
one subject to another, and from the first time point to the following time points, in longitudinal 
studies. 
4. Considering the hardware, the same coil has to be used during an MR protocol both in cross-
sectional and longitudinal studies. When upgrades or repairs are needed during the study 
period, a strategy should be in place to scan some participants twice, before and after the 
upgrade, to estimate the potential bias for a posteriori analyses. Otherwise, the imaging 
protocol and hardware should be kept as constant as possible over the whole time of the study. 
 
b) recommendations to evaluate given the targeted trade-off between sensitivity and 
variability 
 
5. Within-centre reproducibility is much higher than between-centre reproducibility. The need for a 
multicentre setup should then be carefully evaluated while taking into account specific aspects 
such as number of participants, subject transportation, data centralization, quality control and 
cost. For multicentre studies, the use of only one vendor or only some models can be an option. 
 
6. In multicentre studies, protocol harmonization is a mandatory step to obtain similar sequences 
with acquisition parameters as close as possible. There is no way to get a perfect 
harmonization of MRI protocols between different vendors and models. Therefore, it is a trade-
off between a high reproducibility of markers (few centres, same vendors) and a sufficient 
statistical power through the recruitment of a large number of subjects, generally in several 
centres with different scanner vendors and models. Specifying acceptable ranges for different 
acquisition parameters may help obtain satisfactory harmonization for large-scale clinical 
studies. 
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7. Spatial resolution is a key parameter in assessing correctly the variation of any MRI marker 
such as brain volumetry, longitudinal atrophy, volume of WMH or quantification of lacunes and 
PVS. Increasing spatial resolution decreases signal-to-noise ratio and increases acquisition 
duration. Sensitivity for quantifying small objects such as lacunes and PVS will be compromised 
if using voxels as big as the object itself or where there is a slice gap. Selection of optimal 
spatial resolution must therefore be targeted to the primary question. 
 
8. When analysing multicentre MRI data, the use of statistical models to take into account the 
induced variability is recommended (adjusting on centre or using random effects models for 
example). 
 
9. While some quantitative MRI markers of SVD are regularly assessed (brain atrophy, WMH 
volume), others are difficult to quantify given their small size in relation to conventional 
anatomical MRI (lacunes, PVS) or their strong dependence on MRI parameters (CMB). High-
field MRI and detailed studies of these particular markers may be performed in studies nested 
within larger studies assessing more common markers in a clinical setting. For CMB 
characterization, SWI or quantitative susceptibility mapping are promising techniques. Since the 
total magnetic susceptibility of a CMB is an intrinsic physical property independent of imaging 
characteristics, mapping CMB by using quantitative susceptibility mapping may be an 
alternative approach more consistent over a wide spectrum of imaging parameters79. 
 
10. It is important for studies to acknowledge that variation is inevitable and they should detail the 
steps that have been made to minimise this variation. 
Conclusion 
 
There is a need to reduce image variability induced by technological choices (coil, MR 
sequence, MR parameters and options) as much as possible in large multicentre research studies and 
clinical trials using MRI in SVD. Indeed, the added variance due to the multicentre setup can be 
deleterious in various applications and should be minimised using multiple approaches. Protocol 
harmonization and a posteriori corrections can help in minimizing biases; minimisation on centre or 
scanner type may also be advisable. Even if several sources of variability have been previously 
evaluated, most studies have focused on brain volume measurements while few have focused on WMH 
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quantification. Further, less is known concerning the sources of variability when quantifying lacunes, 
CMB and PVS. Additional studies are warranted to investigate the variability of these makers, which is a 
key aspect for future longitudinal or multicentre studies. Other potential SVD-related MRI markers 
derived from new and multiple techniques (such as diffusion tensor imaging, arterial spin labelling, 
magnetization transfer mapping, blood-brain barrier permeability imaging, BOLD functional MRI, cortical 
morphology, cortical microinfarcts, cortical superficial siderosis) will also have to address these 
important questions regarding their reproducibility to facilitate large-scale, multicentre research. 
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Titles and legends to figures 	  
Figure 1 title: Schematic view of the different sources of variability in a multicentre MRI study 
(adapted from www.imaios.com) 
 
Figure 2 title:  Enhanced lesion detection in 3D FLAIR sequence (courtesy of Polak et al. 42) 
Figure 2 legend: Sagittal slices from (a, d) 3D FLAIRED (a FLAIR sequence optimized in order to 
enhance detection of lesions); (b, e) GE 3D FLAIR; and (c, f) 2D FLAIR. Note increased lesion 
detection in the frontal lobe (1) deep white matter (2) and juxtacortical (3) regions with 3D FLAIRED. 
Improved deep white matter lesion (4) detection and resolution in 3D FLAIRED compared to other 
sequences. Cerebellar lesion (5) detected in 3D FLAIRED and GE 3D FLAIR, but uncertainly discerned 
in 2D FLAIR.  
 
Figure 3 title:  Effect of slice thickness, sequence and magnetic field on CMB detection (courtesy 
of Nandigam et al. 28) 
Figure 3 legend: The pairs of images illustrate comparisons of thick-section GRE (A) versus thin-
section SWI (B); thin-section GRE (C) versus thin-section SWI (D); thick-section GRE (E) versus thin-
section GRE (F) (all preceding images at 1.5T); and SWI at 1.5T (G) versus SWI at 3T (H). The black 
arrows in (A) and (B) illustrate a CMB prospectively counted on both sequences, whereas lesions 
denoted by white arrows were initially identified only on the SWI image. The black arrows in the 
remaining images highlight lesions on the paired images for comparison. 
 
Figure 4 title:  Typical gradient distortion field in a T1-weighted acquisition (courtesy of 
Caramanos et al. 112) 
Figure 4 legend: Sagittal, coronal, and axial views of a phantom-based gradient distortion field that was 
determined based on a T1-weighted acquisition. The color scale represents the distance (in millimeters) 
that a voxel moves because of gradient distortion between its “real” location and its “apparent” location 
on such an MRI scan that has not been corrected for the gradient distortion. 
  
